Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial

EUN HYE PARK, a HEE-SUK LIM, b SEUNGHEE LEE, c KYOUNGHWAN ROH, c KWANG-WON SEO, c KYUNG-SUN KANG, c, d KICHUL SHIN b, c

Key Words. Clinical trial • Mesenchymal stem cell • Rheumatoid arthritis • Safety • Umbilical cord blood

ABSTRACT

Based on immunomodulatory actions of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs), in vitro or preclinical studies of hUCB-MSCs have been conducted extensively in rheumatoid arthritis (RA). However, few human trials have investigated the outcomes of hUCB-MSC infusions. The CURE-iv trial was a phase I, uncontrolled, open label trial for RA patients with moderate disease activity despite treatment with methotrexate. The patients received a single intravenous infusion of $2.5 \times 10^7$, $5 \times 10^7$, or $1 \times 10^8$ cells of hUCB-MSCs for 30 minutes, three patients in each cluster, with an increment of cell numbers when there was no dose-limited adverse event. Clinical and safety assessments were performed during the study period, and serum cytokines were measured at baseline and 24 hours after the infusion. Out of 11 screened RA patients, 9 were enrolled. The participants were predominantly female (78%) and the mean age was 57.4 years. The mean disease duration was 9.5 years, and baseline 28-joint disease activity score (DAS28; using erythrocyte sedimentation rate) was 4.53. There was no major toxicity in all clusters up to 4 weeks after the infusion. Serum erythrocyte sedimentation rate changes at 4 weeks ($n = 9$) were $-7.9 \pm 10.4$ ($p = .0517$) and DAS28 changes were $-1.60 \pm 1.57$ ($p = .0159$). Reduced levels of IL-1β, IL-6, IL-8, and TNF-α at 24 hours were observed in the cluster infused with $1 \times 10^8$ MSCs. This phase Ia hUCB-MSC infusion trial for established RA patients revealed no short-term safety concerns.

SIGNIFICANCE STATEMENT

This is the first human trial that has investigated the outcome of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) infusions in patients with rheumatoid arthritis (RA). RA patients with moderate disease activity were given a single infusion of hUCB-MSCs, cell numbers up to $1 \times 10^8$, and no ominous short-term safety signal was observed. In addition, a single infusion of hUCB-MSCs reduced the mean 28-joint disease activity score of the study participants. Data from this trial provide insight and suggestions for future trials assessing safety plus clinical efficacy, furthering treatment protocols of hUCB-MSC infusions for RA patients who are in need.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder that primarily involves synovial joints [1]. During the past decade, new classes of disease-modifying antirheumatic drugs (DMARDs) and updated treatment strategies enabled better clinical outcomes for RA patients, but few patients reach long-term drug-free clinical remission despite such achievements. Moreover, these approaches are costly and may ensue side effects, for instance, laboratory test abnormalities and serious infections [2, 3]. Therefore, the need still exists for an effective and safe treatment for those who respond inadequately to current therapies.

MSCs are mesoderm-derived cells that reside in the stroma of solid organs and function as precursors of nonhematopoietic connective tissues [4–6]. They can exert profound immunosuppression by modulating the proliferation and differentiation of T and B cells, dendritic cell maturation, and natural killer...
activity [6]. After in vivo administration, MSCs induce peripheral tolerance and migrate to injured tissues where they can inhibit the release of inflammatory cytokines and promote the survival of damaged cells [7]. Based on the immunoregulatory capabilities of MSCs, cell-based therapies using MSCs have been spotlighted as a promising tool for the treatment of various immune-related diseases, such as the graft-versus-host disease, inflammatory bowel disease, multiple sclerosis, and atopic dermatitis [8–12]. Some studies have also demonstrated that MSCs could be part of a new effective therapeutic approach for autoimmune arthritis [12–16].

The main sources of human MSCs are the bone marrow, peripheral blood, adipose tissue, and the umbilical cord. Compared with bone marrow-derived MSCs, human umbilical cord blood-derived MSCs (hUCB-MSCs) have distinct advantages, including accessibility, a higher proliferation capacity, and a lower immunogenicity [17]. In addition to well-documented self-renewal and multipotent differentiation properties, hUCB-MSCs possess immunoregulatory traits that permit allogeneic transplantation [18]. However, the role of hUCB-MSCs in vivo and their repair mechanisms in RA has not yet been fully elucidated.

To our knowledge, this is the first human trial that has investigated the outcome of hUCB-MSC infusions in patients with RA. A recent study used human umbilical cord (hUC)-derived MSCs to RA patients, which differ from hUCB-MSC in terms of source and preparation of the investigational product [19]. Our group has previously investigated the detailed mechanism by which hUCB-MSC infusions can ameliorate inflammatory arthritis [12]. This phase Ia study extends our preclinical research, investigating the safety and tolerability of a single intravenous infusion of hUCB-MSCs in Korean patients with RA.

**MATERIALS AND METHODS**

**Patient Population**

This study enrolled adults (>18 years) with RA who fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism classification criteria [20] and had a baseline 28-joint count disease activity score (DAS28; using the erythrocyte sedimentation rate [ESR]) > 3.2. The requirement for all patients was to be on a stable dose of methotrexate (MTX), for at least 12 weeks. The exclusion criteria were as follows: a history of or current rheumatic diseases or an autoimmune joint disease other than RA, a functional class IV status as defined by the ACR Classification of Functional Status in RA [21], pregnancy or breastfeeding, a prior malignancy, or an active infection. Patients with a history of incompletely treated tuberculosis, or a conspicuous infection within 4 weeks before screening were also excluded.

**Study Design**

The Clinical and safety assessment of human Umbilical cord blood-derived mesenchymal stem cell therapy for RhEumatoid arthritis patients administered intravenously (CURE-iv) trial is a phase Ia, open-label, dose-escalation study for RA patients with a moderate disease activity despite treatment with MTX (ClinicalTrials.gov NCT02221258). The subjects were recruited from the Seoul Metropolitan Government-Seoul National University Boramae Medical Center. The study was approved by institutional review boards and ethics committees at Korea National Institute for Bioethics Policy, and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent before the investigation. Patients maintained their regimen of conventional DMARDs and oral corticosteroids (<10 mg/day of prednisolone or its equivalent) throughout the study period.

The hUCB-MSCs were isolated and maintained as previously described [22]. Briefly, hUCB samples were obtained from the umbilical vein immediately after delivery and were mixed with Hetasep solution (StemCell Technologies, Vancouver, Canada) at a ratio of 5:1, and then incubated at room temperature. The supernatant was collected, and mononuclear cells were obtained using Ficoll (GE healthcare life sciences, Pittsburgh, PA) density-gradient centrifugation, according to the manufacturer’s protocol [23]. The cells were washed twice in phosphate buffered solution. Next, the cells were seeded at a density of $2 \times 10^7$ to $2 \times 10^8$ cells/cm$^2$ on plates in growth media that consisted of D-media (formula 78-5470EF; Gibco BRL, Grand Island, NY) containing EGM-2 SingleQuot and 10% fetal bovine serum (Gibco BRL). After 3 days, nonadherent cells were removed [24]. The stem cell characteristics of hUCB-MSCs were verified by determining their differentiation, proliferation, and immunological phenotypes as previously described [25]. The subjects were given a single intravenous infusion of $2.5 \times 10^7$, $5 \times 10^7$, or $1 \times 10^8$ cells of hUCB-MSCs for 30 minutes. Three patients were allocated to each cluster. The first cluster received the lowest cell number and then moved (increased hUCB-MSC numbers) to the next cluster if there was no dose-limited adverse event. Clinical and safety parameters were monitored after 24 hours, 72 hours, 1 week, and 4 weeks following the infusion (Fig. 1). Hematological and biochemical tests, urine analysis, chest radiography, and a 12-lead electrocardiogram (ECG) were performed. For the disease state assessment, values from a 66/68-swollen/tender joint count, DAS28, a pain visual analog scale (VAS), and a health assessment questionnaire (HAQ) were obtained. Serum cytokines, including IL-1β, IL-6, IL-8, IL-10, and TNF-α, at baseline and 24 hours after the infusion of hUCB-MSC were analyzed with a Human High Sensitive T Cell Magnetic Bead Panel (Merck KGaA, Darmstadt, Germany).

**Outcomes**

The primary study objective was to evaluate the safety and tolerability of a single intravenous infusion of hUCB-MSCs in study subjects. The secondary objective was to obtain a preliminary assessment of its efficacy. For the efficacy end points, changes of DAS28 and HAQ 4 weeks after the infusion were evaluated.

**Statistical Analysis**

Continuous variables from the clinical data were presented as means and standard deviations. Discrete variables were reported as frequencies and proportions. The data for the safety evaluation before and after the treatment were compared by paired t tests or the Wilcoxon signed-rank test. The statistical significance of the analyses’ results was determined by a two-tailed $p$ value of <.05.
RESULTS

Patient Characteristics

Out of the 11 screened RA patients, 9 were enrolled and received a single intravenous infusion of hUCB-MSCs (Fig. 2). The cell numbers of hUCB-MSCs infused to each patient were $2.5 \times 10^7$ ($n=3$), $5 \times 10^7$ ($n=3$), and $1 \times 10^8$ ($n=3$). The study subjects were predominantly female (78%) and the mean age was 57.4 years. The disease duration was (mean $\pm$ SD) 9.5 $\pm$ 8.7 years and the DAS28 at baseline was 4.53 $\pm$ 1.35. All subjects had received MTX, with mean doses of 14.2 mg/week at baseline and seven of them were taking oral corticosteroids (Table 1). No patient had previously received biologic DMARDs.

Safety and Tolerability

There was no ominous safety signal in all clusters up to 4 weeks after the infusion of hUCB-MSCs. The vital signs were stable during the hUCB-MSC infusion and clinically meaningful ECG changes could not be observed. Only one patient in the $5 \times 10^7$ group reported joint pain 60 minutes after the infusion, but this was determined to be unrelated to the hUCB-MSCs infusion. There was no major abnormal finding in the hematologic profiles (Table 2). Abnormalities were not observed in the serum chemical profiles such as of liver and renal functions. Serum uric acid levels were slightly elevated (from 3.63 $\pm$ 1.11 to 4.16 $\pm$ 1.19 mg/dl) at 4 weeks, but the changes were minor and there was no related adverse event. Neither serious adverse event nor dose-limiting toxicity (DLT) was reported.

Changes in Disease Activity

The ESR and C-reactive protein level changes from baseline to week 4 were $-7.9 \pm 10.4$ mm/hour ($p = .0517$) and $-0.37 \pm 1.09$ mg/dl ($p = .3362$), respectively (Table 2). At 4 weeks after the hUCB-MSCs infusion, the DAS28 reduction was statistically significant ($-1.60 \pm 1.57$ mm/hour, $p = .0158$; Table 1). The HAQ score and pain VAS changes at week 4 were $-0.15 \pm 0.48$ ($p = .3706$), and $-17.9 \pm 27.7$ ($p = .0885$), respectively. Serum levels of IL-1$\beta$, IL-6, IL-8, IL-10, and TNF-$\alpha$

| Period | Screening | Treatment | Closing |
|--------|-----------|-----------|---------|
| Visit  | 1         | 2         | 3       | 4       | 5       | 6       |
| Days (d) | -14d     | -1d       | 0d      | 1d      | 7d+3d   | 28d+3d  |

Figure 1. Step-wise increment of human umbilical blood-derived mesenchymal stem cell infusion. Abbreviations: DLT, dose limiting toxicity; MTD, maximum tolerated dose.

Figure 2. Overview of the study scheme.
Table 1. Baseline clinical and demographic characteristics of patients (n = 9)

|                          | Baseline | Week 4 | p value |
|--------------------------|----------|--------|---------|
| Female, n (%)            | 7 (77.8) |        |         |
| Age, mean ± SD, yr       | 57.4 ± 10.0 |       |         |
| Disease duration, mean ± SD, yr | 9.5 ± 8.7 |       |         |
| BMI, mean ± SD, kg/m²    | 25.2 ± 0.9 |        |         |
| Rheumatoid factor, positive, n (%) | 6 (66.7) |        |         |
| Anti-CCP, positive, n (%) | 4 (44.4) |        |         |
| Previous medication      |          |        |         |
| MTX users, n (%)         | 9 (100.0) |        |         |
| Dose, mean ± SD, mg/wk   | 14.2 ± 0.9 |        |         |
| Corticosteroid users, n (%) | 7 (77.8) |        |         |
| Dose, mean ± SD, mg/day² | 3.1 ± 0.8 |        |         |
| Swollen joint count, mean ± SD, n | 2.4 ± 2.7 | 0.7 ± 0.8 | .1038 |
| Tender joint count, mean ± SD, n | 11.8 ± 16.7 | 2.0 ± 3.1 | .0888 |
| DAS28-ESR, mean ± SD    | 4.53 ± 1.35 | 2.93 ± 1.22 | .0158 |
| Pain VAS (0–100), mean ± SD, mm | 64.8 ± 20.2 | 46.9 ± 29.1 | .0885 |
| HAQ (0–5), mean ± SD    | 0.69 ± 0.63 | 0.54 ± 0.58 | .3706 |

*Prednisolone or its equivalent.
Abbreviations: CCP, cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; DAS28, 28-joint disease activity score; VAS, visual analog scale; HAQ, health assessment questionnaire.

Table 2. Laboratory tests at baseline and week 4

|                          | Baseline | Week 4 | Changes | p value |
|--------------------------|----------|--------|---------|---------|
| WBC, mean ± SD, x10⁷/mm³ | 7.99 ± 2.68 | 8.23 ± 3.30 | 0.23 ± 1.14 | .5555 |
| ANC, mean ± SD, mm³      | 5,992.6 ± 2642.9 | 5,558.3 ± 2793.4 | 434.2 ± 1,225.6 | .3594 |
| Hematocrit, mean ± SD, % | 38.5 ± 4.3 | 38.9 ± 4.8 | 0.3 ± 1.8 | .5852 |
| Platelet, mean ± SD, mm³ | 292.1 ± 72.6 | 281.67 ± 78.8 | -10.4 ± 22.2 | .1961 |
| ESR, mean ± SD, mm/hr    | 23.3 ± 12.0 | 15.4 ± 9.2 | -7.9 ± 10.4 | .0517 |
| Hs-CRP, mean ± SD, mg/dl | 0.81 ± 1.12 | 0.44 ± 0.47 | -0.37 ± 1.09 | .3362 |
| Total protein, mean ± SD, g/dl | 6.74 ± 0.28 | 6.83 ± 0.53 | 0.09 ± 0.43 | .5537 |
| Albumin, mean ± SD, g/dl | 4.21 ± 0.14 | 4.19 ± 0.13 | -0.02 ± 0.12 | .5943 |
| Total bilirubin, mean ± SD, mg/dl | 0.60 ± 0.17 | 0.61 ± 0.25 | 0.01 ± 0.19 | .8651 |
| AST, mean ± SD, IU/l     | 20.2 ± 5.3 | 23.56 ± 9.7 | 3.33 ± 6.4 | .1570 |
| ALT, mean ± SD, IU/l     | 17.0 ± 4.9 | 20.56 ± 10.6 | 3.56 ± 8.4 | .2390 |
| BUN, mean ± SD, mg/dl    | 11.9 ± 2.6 | 13.2 ± 3.9 | 1.3 ± 3.6 | .2995 |
| Creatinine, mean ± SD, mg/dl | 0.66 ± 0.06 | 0.64 ± 0.09 | -0.01 ± 0.09 | .6246 |
| Glucose, mean ± SD, mg/dl | 108.2 ± 12.9 | 104.6 ± 8.3 | -3.7 ± 14.7 | .4566 |
| Total cholesterol, mean ± SD, mg/dl | 179.0 ± 30.5 | 186.3 ± 27.3 | 7.3 ± 16.4 | .2168 |
| Triglyceride, mean ± SD, mg/dl | 100.9 ± 29.6 | 126.8 ± 54.0 | 25.9 ± 63.9 | .2587 |
| Uric Acid, mean ± SD, mg/dl | 3.63 ± 1.11 | 4.16 ± 1.19 | 0.52 ± 0.57 | .0242 |

Abbreviations: ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate transaminase; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; hs-CRP, high sensitivity C-reactive protein; MTX, methotrexate; WBC, white blood cell.

This phase Ia study demonstrated that a single intravenous infusion of hUCB-MSCs resulted in a favorable safety profile for our subjects with RA. The patients were given a single infusion of hUCB-MSCs, with cell numbers up to 1 × 10⁷, and no DLT was reported. No major toxicity was observed up to 4 weeks after each infusion of hUCB-MSCs. With regard to efficacy assessment, disease activity change was not the primary objective of this study, but a single infusion of hUCB-MSCs reduced the mean DAS28 at week 4.

MSCs reportedly have the capabilities to modulate immune responses as well as to heal damaged tissues and organs [26]. They secrete a multitude of cytokines and growth factors with immunosuppressive properties, which inhibit B and T cell proliferation as well as monocyte maturation [6]. MSCs also promote the generation of Treg cells and M2 macrophages [27–29]. In addition, they are considered to possess a low immunogenicity due to their limited expression of the major histocompatibility complex (MHC) I, the lack of MHC expression as well as of costimulatory molecules, and the
Stem Cell Infusion for Rheumatoid Arthritis

which attenuate the severity of arthritis comparable to bio-
inducing Tregs, and inhibiting the generation of Tfh cells.

hUCB-MSCs demonstrably correct an immunity imbalance by
flvated macrophages and also accelerated anti-in
hUCB-MSCs downregulate the secretion of TNF-
induced FLS apoptosis and promoted chondrogenesis [42].

In vitro or preclinical studies have extensively examined
the immunomodulatory actions of UCB-MSCs in RA. UCB-
MSCs exert a profound inhibitory effect on the proliferation,
invasive behavior, and in
MSCs exert a profound inhibitory effect on the proliferation,
the immunomodulatory actions of UCB-MSCs in RA. UCB-
induced osteoclastogenesis [40].

In a prior phase I study of hUC-MSC infusions in Chinese
patients with active RA, the subjects received 4 × 10^7 cells of
hUC-MSCs via an intravenous infusion, with some patients
being additionally infused with hUC-MSCs at 3-month intervals
after the first treatment. The infusions were well tolerated and
no major abnormalities were observed [19]. In our study,
the patients were given a single infusion of hUCB-MSCs but a
higher cell number of up to 1 × 10^8. However, no subjects
exhibited an infusion reaction, a serious adverse event, or
major abnormalities in serum chemical or hematologic profiles,
both during and after the treatment. Although increased mean
serum uric acid levels were observed, they were within the
normal range, the changes were trivial, and no related AE was
discovered throughout the study. Nevertheless, we plan to
monitor serum uric acid levels in the future trials with
repeated infusions. A randomized, placebo-controlled, phase
lb/Ia trial recently demonstrated the safety of repeated infu-
sions (days 1, 5, and 18) of adipose-derived MSCs in patients
with active RA; a trend for clinical efficacy was observed, yet it
did not persist beyond 3 months after the infusion [16].

This study has some limitations. First, the sample size
was relatively small and the duration of the follow-up period
after the infusion of hUCB-MSCs was short for the explora-
tion of long-term safety; we are currently conducting a
5-year observational study to search for any safety signal in
our subjects. Also, there was no placebo group for further
comparison with the hUCB-MSC recipients. Second, the
administration of a single infusion of hUCB-MSCs is prohibi-
tive in determining whether repetitive infusions would have
similar safety outcomes. Third, among the study participants
no one was exposed to biologic DMARDs; future trials are
planned to be enrolled, if not limited to, previous biologic users.
Lastly, although a range of clinical outcomes was assessed,
imaging studies were excluded due to the short follow-up
period. Future investigations including long-term radi-
ographic outcomes in hUCB-MSC-treated patients would be
interesting.

**Conclusion**

This is the first phase la study of RA patients that evaluated
the safety and tolerability of a single intravenous infusion
with hUCB-MSCs and with cell numbers of up to 1 × 10^8,
revealing an acceptable safety profile. Conclusions regarding
efficacy in phase I trials are limited, and although evaluation
of disease activity was not the primary objective of this
study, a single infusion of hUCB-MSCs effectively reduced the
mean DAS28 at week 4. Considering favorable safety profiles,
intravenous infusion of hUCB-MSCs may constitute a therape-
utoptic option for patients with RA, who are refractory to or
intolerant of MTX. There is a wide array of opportunities for
future clinical studies with different hUCB-MSC infusion strat-
egies in which safety profiles should be carefully monitored
and outcome measures further refined for optimized effec-
tiveness evaluations.

**Acknowledgments**

We thank Junghyun Yoon for her help enrolling patients and
certifying this trial.

**Author Contributions**

E.H.P.: collection of data, data analysis and interpretation,
manuscript writing, final approval of manuscript; H.-s.L.: collec-
tion of data, data analysis and interpretation; S.L.: data anal-
ysis and interpretation; K.R., K.-W.S., and K.-S.K.: financial
support; K.S.: conception and design, collection of data, data
analysis and interpretation, manuscript writing, final approval
of manuscript.
Therapeutics at Kangstem Biotech Co., Ltd. The other authors indicated no potential conflicts of interest.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
This study was funded by Kangstem Biotech Co., Ltd.; S.L., K.R., K.-W.S. and K.-S.K. work in the department of Stem Cell

REFERENCES
1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;65:307-310.
2. Bongartz T, Sutton AJ, Sweijting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomised controlled trials. JAMA 2006;295:2275-2285.
3. Satliot C, Gossel C, Rayssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 705 patients. Rheumatology 2007;46:327-334.
4. Pitterner MF, Macay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
5. Zuki PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228.
6. Greisch S, Abogresha N, Abdel-Hady Z et al. Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model. World J Stem Cells 2012;4:101-109.
7. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
8. Introna M, Rambaldi A. Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: Successes and hurdles. Curr Opin Organ Transplant 2015;20:72-78.
9. Nagoshi K, Arimura Y, Fujimiy M. Stem cell therapy for inflammatory bowel disease. J Gastroenterol 2015;50:280-286.
10. Glenn JD, Smith MD, Calabresi PA et al. Mesenchymal stem cells differentially modulate effector CD8+T cell subsets and exacerbate experimental autoimmune encephalomyelitis. Stem Cells 2014;32:2744-2755.
11. Kim HS, Yun JW, Shin TH et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells 2015;33:1254-1266.
12. Shin TH, Kim HS, Kang TW et al. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammation activation to alleviate rheumatoid arthritis. Cell Death Dis 2016;7:2524.
13. Mohanty ST, Kottam L, Gambardella A et al. Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther 2010;12:R149.
14. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009;60:1006-1019.
15. Augello A, Tasso R, Negrini SM et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007;56:1175-1186.
16. Alvaro-Gracia JM, Jouer JA, Garcia-Vicuna R et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multi-centre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/la clinical trial. Ann Rheum Dis 2017;76:196-202.
17. Lu LL, Liu YJ, Yang SG et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006:91:1017-1026.
18. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007;25:1384-1392.
19. Wang L, Wang L, Cong X et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev 2013;22:3192-3202.
20. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
21. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
22. Kim HS, Shin TH, Lee BC et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 2013;145:1392-1403.
23. Yang SS, Kim NR, Park KB et al. A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease. Int J Stem Cells 2013;6:37-44.
24. Yu KR, Lee JY, Kim HS et al. A p38 MAPK-mediated alteration of COX-2/PGE2 regulates immunomodulatory properties in human mesenchymal stem cell aging. PLoS One 2014;9:e102426.
25. Seo Y, Yang SR, Jee MK et al. Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick type C1 mice. Cell Transplant 2011;20:1033-1047.
26. Uccelli A, Moretta L, Pistoia V. Immuno-regulatory function of mesenchymal stem cells. Eur J Immunol 2006;36:2566-2573.
27. Gao F, Chiu SM, Motan DA et al. Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis 2016;7:e2062.
28. Selmanini Z, Naj A, Zidi I et al. Human leukocyte antigen-G6 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26:212-222.
29. Francois M, Romieu-Moure R, Li M et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012;20:187-195.
30. The WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-397.
31. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:1-11.
32. Chen M, Su W, Lin X et al. Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum 2013;65:1181-1193.
33. MacDonald GL, Augello A, De Bari C. Role of mesenchymal stem cell in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum 2011;63:2547-2557.
34. Gu Y, Shi S. Transplantation of gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis. Arthritis Res Ther 2016;18:262.
35. Oliveto B, Simonini G, Ciullini S et al. Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis. J Rheumatol 2009;36:2017-2024.
36. Lopez-Santalla M, Mancheco-Convo P, Menta R et al. Human adipose-derived mesenchymal stem cells modulate experimental autoimmune arthritis by modifying early adaptive T cell responses. Stem Cells 2015;33:3493-3503.
37. Liu R, Li X, Zhang Z et al. Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis. Sci Rep 2015;5:12777.
38. Choi JJ, Yoo SA, Park SJ et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008;153:269-276.
39. Gonzalez-Rey E, Gonzalez MA, Varela N et al. Human adipose-derived mesenchymal stem cells...
mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010;69:241-248.

40 Garimella MG, Kour S, Piprode V et al. Adipose-derived mesenchymal stem cells prevent systemic bone loss in collagen-induced arthritis. J Immunol 2015;195:5136-5148.

41 Liu Y, Mu R, Wang S et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010;12:R210.

42 Zeng J, Wang F, Mao M. Coculture of fibroblastlike synoviocytes with umbilical cord-mesenchymal stem cells inhibits expression of proinflammatory proteins, induces apoptosis and promotes chondrogenesis. Mol Med Rep 2016;14:3887-3893.

43 Sun Y, Kong W, Huang S et al. Comparable therapeutic potential of umbilical cord mesenchymal stem cells in collagen-induced arthritis to TNF inhibitor or anti-CD20 treatment. Clin Exp Rheumatol 2017;35:288-295.

See www.StemCellsTM.com for supporting information available online.